Some reports in gastric cancer, liver cancer, and other tumors have found that upregulation of the DIP2A–FSTL1 signaling axis correlates with poor prognosis or greater tumor aggressiveness, implying that this axis may enhance tumor cell proliferation, migration, and invasion, thereby accelerating disease progression (Kudo-Saito et al., 2024). The gene discussed is FSTL1; the disease is neoplasm.